The combined PEG-IFN and RBV therapy needed to be discontinued in 3 of the 24 patients (12.5%), and the RBV dose needed to be reduced in 7 of the patients (29.2%) due to the development of anemia (Hb ≤ 10 g/dL). The gene discussed is GSTM1; the disease is anemia.